Related Experiment Video
Updated: Mar 18, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Entrectinib-Induced Sinus Bradycardia in a Patient With Metastatic Non-Small Cell Lung Cancer
Azita H Talasaz1, Anne J Goldberg2, Catherine A Shu3
1Department of Pharmacy, New York Presbyterian Hospital/Columbia University Medical Center, New York, New York, USA.
Entrectinib, a targeted therapy for non-small cell lung cancer, can cause rare but serious sinus bradycardia. Patients on ALK/ROS1 inhibitors require cardiac monitoring and multidisciplinary care.
Area of Science:
- Oncology
- Pharmacology
- Cardiology
Background:
- Tyrosine kinase inhibitors have improved non-small cell lung cancer (NSCLC) outcomes.
- Entrectinib is effective for ROS1-positive NSCLC, including brain metastases.
- Rare cardiac adverse events are associated with entrectinib.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
07:30Electromagnetic Navigation Transthoracic Nodule Localization for Minimally Invasive Thoracic Surgery
Published on: May 4, 2022
Related Concept Videos
Decreased pulse rate
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ECG Interpretation of Arrhythmias I: Sinus Arrhythmias
Types of Arrhythmias
Sinus Node Arrhythmias
Sinus Bradycardia: Originating from the sinoatrial (SA) node, sinus bradycardia involves slower impulses, resulting in a heart rate of less than 60 beats per minute (bpm). Causes include sleep, vagal stimulation, beta-blockers, hypothyroidism,...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Dysrhythmias IV: Characteristics of Bradyarrhythmias
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase